
Daniel R. Lasoff¹*, Cynthia H. Koh¹, Bryan Corbett¹, Alicia B. Minns¹, F. Lee Cantrell²

¹University of California San Diego - Department of Medical Toxicology
200 W Arbor Drive #8676, San Diego, California 92103

²California Poison Control System - San Diego Division,
200 W. Arbor Drive, San Diego, California 92103-8925

*Corresponding author:
University of California San Diego - Department of Medical Toxicology
200 W Arbor Drive #8676, San Diego, California 92103

e-mail: dlasoff@ucsd.edu

Keywords: Loperamide, Cardiotoxicity, Toxicology, Epidemiology, Drug safety

Conflict of Interest: The authors have no conflict of interest to declare

Abstract

Study Objective: With the increasing amount of information available on the Internet describing techniques for using loperamide either for self-treatment of opioid withdrawal syndromes or for recreational use ("legal highs"), the objective was to describe a statewide

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/phar.1885
This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
abundance of online instructions on how to abuse this drug. Almost all cases of recorded cardiotoxicity occurred over the last 3 years. Cardiotoxicity from loperamide abuse has only recently been recognized as a potential complication during the last few years, so it is likely that earlier cases of cardiotoxicity resulting from loperamide abuse were missed. **Conclusion:** Our data suggest that loperamide may be increasing in popularity as a drug of abuse and for treatment of opioid withdrawal symptoms. Given the potential for significant toxicity with loperamide exposure, including life-threatening cardiac dysrhythmias, clinicians should consider obtaining a screening electrocardiogram for patients presenting after acute or chronic high-dose ingestions of loperamide. In addition, increased control over the availability of loperamide may be warranted.

Loperamide is a readily available over-the-counter medication used to treat diarrhea. The drug functions pharmacologically as a peripherally acting μ-opioid receptor agonist in the gastrointestinal tract. In previous studies, loperamide has been reported to be both safe and effective, with minimal adverse events when used at the recommended therapeutic dosage. The recommended dosage of loperamide is 4 mg orally for acute diarrhea followed by 2 mg after each loose stool, and this dosage regimen appears to be well tolerated in adults. Early reports of significant loperamide toxicity after administration of therapeutic doses were described in several infants in Southeast Asia who developed respiratory depression after the use of a loperamide drop formulation for diarrhea. This formulation was removed from the market shortly thereafter; however, today loperamide remains available in multiple over-the-counter preparations worldwide. Since roughly 2008 and rapidly increasing through 2011, descriptions of loperamide misuse began to
appear in various online recreational drug use forums. Users described opioid-like highs and treatment of opioid withdrawal symptoms when loperamide was ingested orally in large quantities. Recently, there have been several reports linking life-threatening and fatal dysrhythmias with high-dose loperamide.

The characteristics surrounding loperamide misuse and abuse are not well described outside of individual case reports. Our goal was to describe a statewide poison control system’s experience with loperamide misuse and abuse, with specific interest in cases of cardiotoxicity, and to determine if there has been a recent increase in reported loperamide misuse or abuse cases.

Methods

The California Poison Control Systems (CPCS) maintains an electronic database (Visual Dotlab Enterprise, Madera, CA) for all calls. The CPCS serves a population of 39 million and receives nearly 300,000 calls annually. CPCS data for each call are collected by trained poison center specialists (i.e., Specialists in Poison Information). For each call, the type and route of exposure, as well as standardized codes for signs, symptoms, and treatments, are all recorded.

We performed a search of the CPCS electronic database from January 1, 2002, through November 10, 2015, for all human cases involving the intentional misuse or abuse of loperamide in patients aged 18 years or older who presented to or referred to a health care facility. Patients were excluded if they did not arrive at the health care facility or if their
outcomes were lost to followup. All patients were de-identified prior to review, and this study was deemed exempt by the University of California San Francisco Committee on Human Research.

An electronic data collection spreadsheet was created using Microsoft Excel software (Microsoft Corp., Redmond, WA). Data collected for each case included age, sex, date of loperamide ingestion, loperamide dose ingested, presenting symptoms, coingestions, reason for loperamide ingestion (abuse, misuse, or unknown), electrocardiogram (ECG) results, QRS/QTc-interval measurement, whether the patient was intubated, length of stay, and final outcome. Abuse was defined as recreational use and dependence, misuse was defined as use for nonindicated symptoms or abnormal dosing for indicated uses, and withdrawal was defined as treatment for opioid withdrawal symptoms. Cardiotoxicity was considered present if patient developed any dysrhythmias, significant ventricular ectopy, widened QRS length (>120 msec), or prolonged QTc interval (>500 msec).

Medical outcomes of loperamide exposure were classified in accordance with the American Association of Poison Control Center’s classification system as minor, moderate, or severe. Minor effects were defined as development of some signs or symptoms as a result of exposure, but they were minimally bothersome and resolved without residual disability or disfigurement. Moderate effects were defined as signs or symptoms that resulted from exposure, were more pronounced, more prolonged, or more systemic in nature than minor effects but resulted in no residual disability or disfigurement. Major effects were defined

This article is protected by copyright. All rights reserved.
as signs or symptoms resulting from exposure that were life-threatening or resulted in residual disability or disfigurement.15

Results
A total of 265 patients who had intentional misuse or abuse of loperamide were identified. Of these, 34 were excluded due to failure to present to the hospital, two were excluded due to miscoding (incorrect medication documented [e.g., diphenoxylate-atropine or bismuth subsalicylate], and five were excluded for loss of follow-up data, leaving 224 patients. Their ages ranged from 18–90 years old; median age was 41 years. One hundred three patients (46%) were male, and 121 (54%) were female. Table 1 details patient demographics and reasons for loperamide ingestion (abuse, misuse, suicide, or unknown). There were 36 cases with minor effects, 49 with moderate effects, nine with major effects, and three deaths. The major effects recorded were respiratory depression, dysrhythmias, and central nervous system depression. Loperamide doses ranged from 8–400 mg daily. Coingestants were identified in two of the three fatalities: methadone and ethanol (one patient), and ethanol and diphenhydramine (one patient). Information regarding coingestants was unavailable for the third patient.

During the years 2002-2015, a mean ± SD of 18.9 ± 6.96 cases of loperamide toxicity were reported each year. We observed a significant spike in incidence in 2014 and 2015, with 41 cases in 2014 and 27 cases through November 2015. Figure 1 depicts the numbers of cases reported each year.
Sixty-four (28.6%) of the 224 patients were admitted to the hospital. For patients in whom a reason could be identified for loperamide use, eight were using loperamide recreationally, 71 were misusing loperamide (nine of which were using it for treatment of opioid withdrawal symptoms), and 83 were using it in a suicide attempt. Another 62 patients were using excessive doses of loperamide for unclear reasons. No patients used loperamide for self-treatment of opioid withdrawal symptoms prior to 2011.

We identified nine cases of cardiotoxicity, with the majority reported in 2012. ECG results were only reported in 20 (9%) of the 224 patients. ECG abnormalities reported included torsade de pointes, ventricular tachycardia, widened QRS interval, and prolonged QTc interval. The cases in which cardiotoxicity occurred are reported in Table 2. Treatments used for cardiotoxicity included sodium bicarbonate, amiodarone, and naloxone.

Discussion

As reported by Daniulaityte in 2013, methods of misuse of loperamide have been described in online forums as early as 2008. A simple online Web search will reveal several drug abuse forums with instructions on how to abuse loperamide recreationally. Given the ever-expanding amount of information available in the public domain, we sought to determine if a recent increase in loperamide calls to a state poison control system has occurred. Although overall rates of calls regarding intentional abuse and misuse of loperamide remained steady through 2002-2013, we did observe a substantial increase in 2014 and again in 2015. It is unclear if this is a new trend or if more calls are being reported due to the recent identification of the potential dangers of loperamide.
A previous poison control study identified 216 cases of loperamide ingestions between November of 1988 and February of 1993.\textsuperscript{16} During this study period, no cases of cardiotoxicity were identified, but several cases of drowsiness and lethargy were noted. This was possibly due to the opioid effects of the drug. Another case report highlighting the central opioid effects of loperamide described a 15-month-old infant who developed respiratory depression, which was reversed by intravenous naloxone.\textsuperscript{17} Several fatalities due to paralytic ileus were also identified in infants in Pakistan who were receiving 2-15 drops of loperamide oral solution (2-mg/ml formulation).\textsuperscript{3}

The risk of severe cardiotoxicity has only recently been recognized following supratherapeutic dosing of loperamide, and this may explain why ECG results were obtained in only 9\% of all patients. It is striking that signs of cardiotoxicity occurred in almost half these patients with all but one occurring after 2012.

The majority of the cases of loperamide cardiotoxicity involved users who reported chronic daily use of high doses. In previously identified cases, success in treating dysrhythmias has been reported with the use of isoproterenol.\textsuperscript{9,10,18,19} Other reported treatments included atropine, amiodarone, lidocaine, and sodium bicarbonate.\textsuperscript{9,10,12,14,18}

Case reports of loperamide toxicity thus far have shown ECGs with widening of the QRS complex, prolongation of the QTc interval, and a Brugada-like pattern, so it remains feasible that high-dose loperamide may interfere with sodium channel conductivity in cardiac
Our study identified similar abnormalities including a Brugada-like pattern, torsade de pointes, ventricular tachycardia, prolonged QTc interval, and widened QRS complex.

Limitations
There were several limitations to our study. The data were collected retrospectively from the poison control center database, which limited the information that could be obtained for each case. ECGs were reported only in a minority of cases.

All data collected by the specialists in poison information were obtained secondhand by reports from either physicians or nurses at the bedside. Additionally, as cardiotoxicity due to loperamide abuse or misuse has been only recently recognized as a potential complication, there may have been several cases in the past that were missed. As we included only cases reported to the poison system in which the patient was evaluated in a health care facility, our results likely do not reflect the overall incidence of loperamide misuse or abuse.

Conclusion
Reports of intentional ingestions of suprtherapeutic doses of loperamide appear to be on the rise, particularly over the past 2 years. Given the recent recognition that loperamide toxicity can lead to life-threatening cardiac dysrhythmias, clinicians should be aware of the potential danger of this potential complication. Clinicians should consider obtaining a screening ECG for patients presenting after acute or chronic high-dose ingestions of
loperamide. In addition, increased control over the availability of loperamide may be warranted.

Table 1. Demographic Characteristics of the 224 Patients and Reasons for Loperamide Ingestion

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>41</td>
</tr>
<tr>
<td>Mean</td>
<td>45.1</td>
</tr>
<tr>
<td>Range</td>
<td>18-90</td>
</tr>
<tr>
<td>Sex, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>103 (46)</td>
</tr>
<tr>
<td>Female</td>
<td>121 (54)</td>
</tr>
<tr>
<td>Reason for ingestion, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Abuse</td>
<td>8 (3.6)</td>
</tr>
<tr>
<td>Misuse</td>
<td>71 (31.7)</td>
</tr>
<tr>
<td>Suicide</td>
<td>83 (37.1)</td>
</tr>
<tr>
<td>Unclear or unknown</td>
<td>62 (27.7)</td>
</tr>
</tbody>
</table>

Figure 1. Number of cases of reported loperamide misuse or abuse by year (through November 2015) in a statewide poison control system.
Table 2. Summary of Cases of Loperamide Abuse or Misuse Involving Cardiotoxicity

<table>
<thead>
<tr>
<th>Patient Demographics</th>
<th>Date</th>
<th>Ingestion size</th>
<th>Reason for Ingestion</th>
<th>Cardiac Abnormalities</th>
<th>Coagagin</th>
<th>Treatments Rendered</th>
<th>Patient Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case #1</td>
<td>65 y.o. F</td>
<td>9/12/06 Unknown</td>
<td>Self treatment of opiate withdrawal</td>
<td>Prolonged QTc of 668ms</td>
<td>None</td>
<td>Atropine, Sodium Bicarbonate, Amiodarone</td>
<td>Death</td>
</tr>
<tr>
<td>Case #2</td>
<td>60 y.o.</td>
<td>9/12/06 Unknown</td>
<td>Self treatment of opiate withdrawal</td>
<td>Wide QRS of 150ms</td>
<td>None</td>
<td>None</td>
<td>Discharged home without complications</td>
</tr>
<tr>
<td>Case #3</td>
<td>60 y.o.</td>
<td>10/15/14 300mg daily</td>
<td>Self treatment of opiate withdrawal</td>
<td>Self treatment of opiate withdrawal</td>
<td>None</td>
<td>None</td>
<td>Discharged home without complications</td>
</tr>
<tr>
<td>Case #4</td>
<td>60 y.o.</td>
<td>1/24/16 200mg daily</td>
<td>Self treatment of opiate withdrawal</td>
<td>ST-T changes</td>
<td>None</td>
<td>None</td>
<td>Discharged home without complications</td>
</tr>
<tr>
<td>Case #5</td>
<td>60 y.o.</td>
<td>4/20/15 200mg daily</td>
<td>Self treatment of opiate withdrawal</td>
<td>Ventricular Tachycardia</td>
<td>Unknown</td>
<td>Amiodarone</td>
<td>Lost to follow up</td>
</tr>
<tr>
<td>Case #6</td>
<td>60 y.o.</td>
<td>6/5/12 Unknown</td>
<td>Self treatment of opiate withdrawal</td>
<td>Prolonged QTc</td>
<td>None</td>
<td>None</td>
<td>Discharged home without complications</td>
</tr>
<tr>
<td>Case #7</td>
<td>60 y.o.</td>
<td>6/6/13 300mg daily</td>
<td>Self treatment of opiate withdrawal</td>
<td>Ventricular Tachycardia</td>
<td>Unknown</td>
<td>Amiodarone</td>
<td>Lost to follow up</td>
</tr>
<tr>
<td>Case #8</td>
<td>60 y.o.</td>
<td>9/12/15 500mg daily</td>
<td>Self treatment of opiate withdrawal</td>
<td>Ventricular Tachycardia</td>
<td>Unknown</td>
<td>Amiodarone</td>
<td>Discharged home without complications</td>
</tr>
</tbody>
</table>

References


This article is protected by copyright. All rights reserved.